The Gut–Kidney Axis: How the Microbiome Shapes Kidney Disease and What the International Society of Nephrology Is Doing About It

For decades, the kidneys and the gut were studied largely in isolation. Nephrologists focused on filtration rates, electrolyte balance, and renal structural damage, while gastroenterologists and microbiologists mapped the vast ecosystem of microorganisms living in the human intestine. Today, those two worlds have converged. A growing body of evidence now points to the gut microbiome — the trillions of bacteria, fungi, and viruses that colonize the digestive tract — as a significant and previously underestimated player in the development and progression of chronic kidney disease (CKD). Understanding this connection opens practical pathways toward new treatments and dietary strategies that could benefit hundreds of millions of people worldwide living with impaired kidney function.

What Is the Gut Microbiome and Why Does It Matter for the Kidneys?

The human gut microbiome is one of the most complex biological ecosystems on earth. A healthy adult harbors approximately 38 trillion microbial cells, collectively encoding more than 150 times the number of genes found in the human genome. These microorganisms perform essential functions: they help digest dietary fiber, synthesize vitamins, train the immune system, and produce a wide array of metabolites that circulate throughout the body.

When this ecosystem is in balance, it supports health. When it falls out of balance — a condition known as dysbiosis — the consequences extend well beyond the gut. Dysbiosis is characterized by a reduction in microbial diversity, a decline in beneficial bacteria, and an overgrowth of potentially harmful microorganisms. Research over the past two decades has linked gut dysbiosis to conditions including obesity, type 2 diabetes, cardiovascular disease, and chronic kidney disease.

The connection between the gut and the kidneys operates through what researchers call the gut–kidney axis: a bidirectional communication network involving microbial metabolites, immune signals, and intestinal barrier integrity.

Dysbiosis in CKD: What the Research Has Found

The first comprehensive, systematic characterization of gut dysbiosis specifically in CKD patients was published by Vaziri and colleagues in the Journal of the American Society of Nephrology in 2013. That landmark study compared the gut microbiota of hemodialysis patients with that of healthy controls and revealed striking differences: patients undergoing dialysis showed a marked depletion of beneficial bacteria responsible for producing short-chain fatty acids (SCFAs), alongside a significant overgrowth of proteolytic bacterial genera. This shift in microbial composition had far-reaching biochemical consequences.

Short-chain fatty acids — particularly butyrate, propionate, and acetate — are produced when gut bacteria ferment dietary fiber. They serve as an energy source for intestinal epithelial cells, help maintain gut lining integrity, and exert anti-inflammatory effects throughout the body. When SCFA-producing bacteria decline, these protective functions are compromised, while proteolytic bacteria generate a different class of compounds: uremic toxins that accumulate in CKD patients and cause widespread harm.

Key Differences in Gut Microbiota: CKD Patients vs. Healthy Individuals

This dysbiotic profile is not merely a consequence of kidney failure — it is increasingly understood as a driver of CKD progression, creating a vicious cycle in which impaired renal function alters the gut environment, which generates metabolites that further damage the kidneys.

A Leaky Gut: How Intestinal Barrier Dysfunction Fuels Inflammation

One of the most important mechanistic links between gut dysbiosis and CKD is disruption of the intestinal barrier — the physical and immunological wall separating the gut lumen from the bloodstream. In healthy individuals, tight junctions between intestinal epithelial cells prevent bacteria and their toxic byproducts from entering systemic circulation. In CKD patients, this barrier is compromised.

As reviewed by Meijers and colleagues in the Journal of the American Society of Nephrology (2010), CKD is associated with increased intestinal permeability. Through this compromised barrier, bacterial components — most notably lipopolysaccharide (LPS), a structural molecule from gram-negative bacteria — translocate into the bloodstream. LPS activates the innate immune system, triggering pro-inflammatory cytokines and sustaining the chronic systemic inflammation that is a hallmark of advanced CKD. This persistent inflammation accelerates kidney damage and cardiovascular deterioration. CKD patients face a dramatically elevated cardiovascular risk compared to the general population, and gut-derived LPS is now recognized as a contributing driver.

Uremic Toxins of Gut Microbial Origin: The Silent Saboteurs

Among the most clinically significant consequences of gut dysbiosis in CKD is the accumulation of uremic toxins that originate specifically from gut microbial metabolism. Unlike small water-soluble molecules that can be efficiently removed by dialysis, several of these microbially derived toxins are protein-bound and highly resistant to conventional renal replacement therapies.

Three compounds have attracted particular scientific attention:

• Indoxyl sulfate (IS): Produced when gut bacteria metabolize the amino acid tryptophan to indole, which is then absorbed and converted by the liver. Indoxyl sulfate promotes renal fibrosis, oxidative stress, and tubular cell injury. It also accelerates vascular calcification, contributing to cardiovascular risk.
• p-Cresyl sulfate (pCS): Derived from tyrosine fermentation by gut bacteria. Like indoxyl sulfate, it is highly protein-bound and accumulates in CKD, contributing to renal and cardiovascular toxicity. Elevated plasma pCS levels have been associated with faster CKD progression and higher all-cause mortality.
• Trimethylamine N-oxide (TMAO): Generated when gut bacteria metabolize dietary precursors such as choline, betaine, and carnitine — compounds found in red meat, eggs, and fish — to produce trimethylamine (TMA), which the liver then oxidizes to TMAO. A landmark epidemiological study by Tang and colleagues, published in the New England Journal of Medicine in 2013, established TMAO as an independent predictor of major adverse cardiovascular events in a cohort of more than 4,000 patients. This finding provided strong mechanistic plausibility for what researchers now describe as the gut–cardiovascular–kidney axis.

These three toxins share a common feature: because the kidneys are primarily responsible for their clearance, impaired renal function leads to their progressive accumulation. The higher the toxin burden, the more damage they inflict, driving a self-perpetuating cycle of renal and cardiovascular harm.

Major Gut-Derived Uremic Toxins: Origins and Effects

Dietary Strategies to Modulate the Gut Microbiome in CKD

If gut dysbiosis contributes to CKD progression, then modifying the microbiome through diet is a compelling and accessible therapeutic strategy. The composition of the microbiome is profoundly shaped by what we eat. Diets rich in plant-based fiber selectively promote SCFA-producing bacteria, while diets high in animal protein provide substrates for proteolytic bacteria that generate uremic toxins.

The KDOQI Nutrition in CKD Clinical Practice Guidelines (Ikizler et al., American Journal of Kidney Diseases, 2020) incorporate dietary protein and fiber recommendations that are partly informed by this microbiome-uremic toxin framework. These guidelines acknowledge that dietary choices affect not only nutrient intake but also the microbial gut environment, which influences the systemic toxin burden in CKD patients.

More specific evidence comes from small randomized trials in Nephrology Dialysis Transplantation showing that prebiotic fiber supplementation in pre-dialysis CKD patients produced measurable reductions in urinary p-cresyl sulfate excretion — a proxy for reduced gut-derived toxin production. While sample sizes are modest, the direction of findings is consistent and scientifically plausible.

Dietary approaches currently under investigation include:

• High-fiber, plant-rich diets to promote SCFA-producing bacteria and reduce protein fermentation
• Prebiotic supplementation (e.g., inulin, fructooligosaccharides) to selectively feed beneficial microbial populations
• Probiotic supplementation to introduce beneficial bacterial strains directly
• Synbiotics (combinations of pre- and probiotics) for synergistic microbiome modulation
• Restriction of dietary precursors of TMAO (red meat, high-fat dairy, eggs) in patients with elevated cardiovascular risk

Each of these strategies has a plausible mechanism, but the translation from biological plausibility to confirmed clinical benefit requires rigorous evidence from well-designed clinical trials.

The Role of the International Society of Nephrology in Advancing This Research

The International Society of Nephrology has played a central role in bringing gut–kidney axis research to the attention of the global nephrology community. Through its flagship journal, Kidney International, and through international educational symposia and congresses, ISN has facilitated the dissemination of emerging microbiome science to nephrologists working across diverse healthcare settings.

ISN (International Society of Nephrology) has also framed microbiome research within its broader global health mission. The World Kidney Day 2020 theme — “Kidney Health for Everyone Everywhere” — reflected the organization’s commitment to equitable kidney care across both high-income and low-resource settings. This theme is directly relevant to microbiome research, as dietary and microbiome-based interventions, if proven effective, could offer relatively low-cost adjunctive therapies suitable for settings where access to dialysis and advanced pharmaceuticals is limited.

The International Society of Nephrology acknowledges, with appropriate scientific caution, that the clinical evidence for microbiome-targeted interventions in CKD remains preliminary. Most available studies are small, short in duration, and powered primarily to detect changes in surrogate biomarkers rather than hard clinical endpoints such as rate of GFR decline, cardiovascular events, or mortality.

What Still Needs to Be Proven: The Path Toward Clinical Translation

For gut microbiome interventions to become standard components of CKD management, several critical knowledge gaps must be addressed. The ISN’s research agenda has consistently emphasized the need for large-scale, adequately powered, randomized controlled trials with robust clinical endpoints. Key questions include:

• Do microbiome-targeted interventions significantly slow the rate of GFR decline in CKD patients?
• Can reducing uremic toxin levels through dietary or prebiotic/probiotic strategies translate into fewer cardiovascular events?
• What is the optimal composition, dose, and duration of fiber or probiotic supplementation for different CKD stages?
• How does CKD etiology (diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis) affect the microbiome response to intervention?
• Are certain patient subgroups — such as those with gut motility disorders or those receiving specific medications like antibiotics or phosphate binders — less likely to benefit from microbiome modulation?

These are not simple questions to answer. The gut microbiome varies enormously between individuals and populations, shaped by genetics, geography, diet, medications, and age. Designing adequately controlled, generalizable trials is methodologically challenging. Nevertheless, the pace of research is accelerating, and tools such as metagenomics, metabolomics, and advanced sequencing are rapidly improving the field’s capacity to answer them.

Implications for Clinical Practice Today

While awaiting large-scale trial evidence, clinicians can already apply several evidence-informed principles from the gut–kidney axis literature:

• Encouraging adequate dietary fiber intake, which supports microbiome diversity and may reduce uremic toxin precursor availability
• Limiting excessive animal protein, which is rich in tryptophan and tyrosine — key substrates for proteolytic bacteria
• Recognizing that antibiotics can profoundly disrupt the gut microbiome and may have unintended consequences for uremic toxin production
• Considering the cardiovascular implications of TMAO-precursor-rich diets in high-risk patients

Conclusion

The gut microbiome is no longer a peripheral concern in nephrology. It sits at the intersection of nutrition, inflammation, toxicology, and cardiovascular biology, and its role in CKD progression is supported by a growing and increasingly robust body of evidence. From the earliest studies identifying dysbiosis in hemodialysis patients to the landmark epidemiological work linking TMAO to cardiovascular events, the science of the gut–kidney axis has advanced considerably over the past two decades. The International Society of Nephrology recognizes both the promise and the limitations of this field. ISN continues to champion high-quality research, international collaboration, and evidence-based education to ensure that advances in microbiome science are translated responsibly and equitably into improved outcomes for the hundreds of millions of people living with chronic kidney disease worldwide. Encouraging adequate dietary fiber intake, moderating excessive animal protein, and remaining alert to the microbiome-disrupting effects of antibiotics are practical steps available to clinicians today — grounded in current science and aligned with the gut–kidney axis evidence base. As our understanding deepens, the gut may prove to be one of the most important therapeutic frontiers in nephrology — one that connects what we eat to how our kidneys age.